Re: Farmas USA
INCY y AGEN
Incyte and Agenus Amend Collaboration Agreement
Agenus will receive today accelerated milestone payments of $20 million from Incyte related to the clinical development of INCAGN1876 (anti-GITR agonist) and INCAGN1949 (anti-OX40 agonist). Across all programs in the collaboration, Agenus will now be eligible to receive up to a total of $510 million in future potential development, regulatory and commercial milestones.
The parties have also entered into a separate Stock Purchase agreement whereby Incyte will purchase 10 million shares of Agenus common stock today at $6 per share.
https://finance.yahoo.com/news/incyte-agenus-amend-collaboration-agreement-120000924.html
Incyte takes over antibody work from Agenus as pair rejig pact
«Después de nada, o después de todo/ supe que todo no era más que nada.»